Saurabh Dahiya, MD, FACP

4.8/5

36 Patient Ratings

23 Patient Reviews

Saurabh Dahiya, MD, FACP

Hematologist-Oncologist

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

View Professional Summary

Additional Languages Spoken:

Hindi

Insurance Coverage

Online Second Opinion Program

Resources for Referring Physicians

Biography

Dr. Saurabh Dahiya is a cancer specialist board-certified in internal medicine, hematology, and medical oncology. He serves as Associate Professor of Medicine at Stanford University School of Medicine and Clinical Director of Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy, where he provides patient-centered care for individuals with cancer.

Dr. Dahiya’s research focuses on advancing cellular immunotherapies for hematologic malignancies, including CAR T-cell platforms and next-generation multiantigen targeting strategies for lymphoma. His work aims to address high tumor bulk disease and develop novel cell therapy approaches that enhance durability and response in hematologic cancers. He leads multiple investigator-initiated and industry-sponsored trials in cellular immunotherapy with a focus on translating correlative research insights into improved patient outcomes.

He has authored more than 100 peer-reviewed publications in journals such as The New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, Blood, and Blood Advances. Dr. Dahiya serves as Hematology Lead Editor for Critical Reviews in Oncology and Hematology and is an active member of ASH, ASTCT, and ASCO. Before joining Stanford, he was on faculty at the University of Maryland’s Greenebaum Comprehensive Cancer Center, where he helped develop the Cellular Immunotherapy Program.

View Full Biography

Professional Summary

Education & Certifications

Board Certification: American Board of Internal Medicine, Hematology (2024)
Board Certification: American Board of Internal Medicine, Medical Oncology (2024)
Fellowship: Cleveland Clinic Foundation (2013) OH
- Fellowship: Stanford University Bone Marrow Transplant Fellowship (2017) CA
- Fellowship: Baystate Medical Center (2016) MA
- Residency, Baystate Medical Center/Tufts University School of Medicine, Internal Medicine Residency (2012)
- Internship: Western Reserve Care System (2010) OH
- Medical Education: Maulana Azad Medical College (2008) India

View More Education & Certifications

Publications

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Ahluwalia, M. S., Xie, H., Dahiya, S., Hashemi-Sadraei, N., Schiff, D., Fisher, P. G., … Peereboom, D. M. (2015). Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. Journal of Neuro-Oncology, 122(1), 111–19.
Bevacizumab in high-grade gliomas: past, present, and future.
Curry, R. C., Dahiya, S., Alva Venur, V., Raizer, J. J., & Ahluwalia, M. S. (2015). Bevacizumab in high-grade gliomas: past, present, and future. Expert Review of Anticancer Therapy, 15(4), 387–397.
Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma.
Ahluwalia, M. S., Bou-Anak, S., Burgett, M. E., Sarmey, N., Khosla, D., Dahiya, S., … Gladson, C. L. (2016). Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma. Journal of Neuro-Oncology.
- Sleep disturbances in cancer patients: Underrecognized and undertreated
  Dahiya, S., Ahluwalia, M. S., & Walia, H. K. (2013). Sleep disturbances in cancer patients: Underrecognized and undertreated. CLEVELAND CLINIC JOURNAL OF MEDICINE, 80(11), 722–732.
- Recurrent or refractory primary central nervous lymphoma: therapeutic considerations
  Dahiya, S., Murphy, E. S., Chao, S. T., Stevens, G. H. J., Peereboom, D. M., & Ahluwalia, M. S. (2013). Recurrent or refractory primary central nervous lymphoma: therapeutic considerations. EXPERT REVIEW OF ANTICANCER THERAPY, 13(9), 1109–1119.
- Primary Central Nervous System Lymphoma in the Elderly: The Cleveland Clinic Experience
  Xie, H., Dahiya, S., Murphy, E. S., Chao, S. T., Suh, J. H., Stevens, G. H. J., … Ahluwalia, M. S. (2013). Primary Central Nervous System Lymphoma in the Elderly: The Cleveland Clinic Experience. ANTICANCER RESEARCH, 33(8), 3251–3258.
- Treatment of Cerebral Radiation Necrosis With Bevacizumab: The Cleveland Clinic Experience
  Sadraei, N. H., Dahiya, S., Chao, S. T., Murphy, E. S., Osei-Boateng, K., Xie, H., … Ahluwalia, M. S. (2015). Treatment of Cerebral Radiation Necrosis With Bevacizumab: The Cleveland Clinic Experience. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 38(3), 304–310.
- Continuing challenges and current issues in acute lymphoblastic leukemia
  Kansagra, A., Dahiya, S., & Litzow, M. (2018). Continuing challenges and current issues in acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 59(3), 526–41.
- Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.
  Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., & Miklos, D. B. (2018). Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. Leukemia & Lymphoma, 1–4.
- Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR-T therapy.
  Dahiya, S., Le, R., Hossain, N. M., Abramian, M., Muffly, L. S., & Miklos, D. B. (2017). Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR-T therapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.
  Frank, M. J., Hossain, N. M., Bukhari, A. A., Dean, E., Spiegel, J. Y., Claire, G. K., … Miklos, D. B. (2019). Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
  Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., … Locke, F. L. (2020). Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1902104.
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
  Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., … Warner, J. L. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England).
- Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.
  Spiegel, J. Y., Dahiya, S., Jain, M. D., Tamaresis, J. S., Nastoupil, L., Jacobs, M. T., … Miklos, D. B. (2020). Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. Blood.
- Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma
  Frank, M. J., Hossain, N., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., … Miklos, D. B. (2019). Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Bennani, N. N., Maurer, M. J., Nastoupil, L. J., Jain, M. D., Chavez, J. C., Cashen, A. F., … Lin, Y. (2019). Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. BLOOD. AMER SOC HEMATOLOGY.
- Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
  Jain, M. D., Jacobs, M. T., Nastoupil, L. J., Spiegel, J. Y., Feng, G., Lin, Y., … Locke, F. L. (2019). Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. BLOOD. AMER SOC HEMATOLOGY.
- Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy
  Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., & Miklos, D. B. (2019). Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. LEUKEMIA & LYMPHOMA, 60(2), 503–506.
- Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
  Frank, M. J., Hossain, N. M., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., … Miklos, D. B. (2021). Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2100377.
- The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
  Bergstrom, C. P., Dahiya, S., Chen, W., Zhang, C. C., Zhu, H., Yan, J., … Kansagra, A. (2021). The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement. Leukemia Research, 100, 106480.
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
  Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., … Westin, J. R. (2021). Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. The New England Journal of Medicine.
- Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
  Jacobs, M. T., Jain, M. D., Gao, F., Nastoupil, L. J., Spiegel, J. Y., Lin, Y., … Locke, F. L. (2022). Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clinical Lymphoma, Myeloma & Leukemia.
- Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium
  Spiegel, J. Y., Jain, M. D., Nastoupil, L., Tamaresis, J., Ghobadi, A., Lin, Y., … Lunning, M. A. (2021). Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. BLOOD. AMER SOC HEMATOLOGY.
- Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium
  Wang, Y., Jain, P., Locke, F. L., Munoz, J., Maurer, M. J., Beitinjaneh, A., … Jain, M. D. (2021). Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. BLOOD. AMER SOC HEMATOLOGY.
- Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium.
  Jain, P., Wang, Y., Locke, F. L., Munoz, J., Beitinjaneh, A., Frank, M. J., … Maurer, M. J. (2022). Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
  Nastoupil, L. J., Dahiya, S., Miklos, D. B., Reagan, P. M., Ulrickson, M., Jung, A. S., … Nahas, M. (2022). KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine.
  Atanackovic, D., Kreitman, R. J., Cohen, J., Hardy, N. M., Omili, D., Iraguha, T., … Rapoport, A. P. (2022). T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine. Journal for Immunotherapy of Cancer, 10(7).
- Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
  Elsawy, M., Chavez, J. C., Avivi, I., Larouche, J.-F. F., Wannesson, L., Cwynarski, K., … Kersten, M. J. (2022). Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood.
- Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy.
  Atanackovic, D., Luetkens, T., Omili, D., Iraguha, T., Lutfi, F., Hardy, N. M., … Dahiya, S. (2022). Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. Blood, 140(2), 152–156.
- Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.
  Saharia, K. K., Husson, J. S., Niederhaus, S. V., Iraguha, T., Avila, S. V., Yoo, Y. J., … Atanackovic, D. (2022). Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine. Clinical & Translational Immunology, 11(5), e1391.
- Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.
  Mumtaz, A. A., Fischer, A., Lutfi, F., Matsumoto, L. R., Atanackovic, D., Kolanci, E. T., … Sunshine, S. B. (2022). Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review. The British Journal of Ophthalmology.
- Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
  Kim, D. W., Bukhari, A., Lutfi, F., Zafforoni, F., Merechi, F., Mustafa Ali, M. K., … Law, J. Y. (2022). Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma. Leukemia & Lymphoma, 63(6), 1339–1347.
- Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
  Dahiya, S., Luetkens, T., Lutfi, F., Avila, S., Iraguha, T., Margiotta, P., … Atanackovic, D. (2022). Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy. Blood Advances, 6(2), 686–689.
- The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
  Nuvvula, S., Dahiya, S., & Patel, S. A. (2022). The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia, 22(6), 362–372.
- Deep dissection of the antiviral immune profile of patients with COVID-19.
  Atanackovic, D., Avila, S. V., Lutfi, F., de Miguel-Perez, D., Fan, X., Sanchez-Petitto, G., … Luetkens, T. (2021). Deep dissection of the antiviral immune profile of patients with COVID-19. Communications Biology, 4(1), 1389.
- The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
  Lutfi, F., Holtzman, N. G., Kansagra, A. J., Mustafa Ali, M., Bukhari, A., Yan, J., … Dahiya, S. (2021). The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma. British Journal of Haematology, 195(3), 405–412.
- Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant.
  Atanackovic, D., Luetkens, T., Avila, S. V., Hardy, N. M., Lutfi, F., Sanchez-Petitto, G., … Rapoport, A. P. (2021). Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant. Vaccines, 9(7).
- Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.
  Lutfi, F., Holtzman, N., Siglin, J., Bukhari, A., Mustafa Ali, M., Kim, D., … Dahiya, S. (2021). Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma. British Journal of Haematology, 192(1), 212–216.
- Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation.
  Godara, A., Siddiqui, N. S., Munigala, S., Dhawan, R., Kansagra, A. J., Rapoport, A. P., … Dahiya, S. (2021). Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation. JCO Oncology Practice, 17(3), e355–e368.
- Severe dysautonomia as a manifestation of neurotoxicity after CAR-T cell therapy for diffuse large B-cell lymphoma.
  El Chaer, F., Siegel, A., Holtzman, N. G., Bukhari, A., Lutfi, F., Shah, N. G., … Dahiya, S. (2020). Severe dysautonomia as a manifestation of neurotoxicity after CAR-T cell therapy for diffuse large B-cell lymphoma. American Journal of Hematology, 95(6), E146–E148.
- Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.
  Bukhari, A., El Chaer, F., Koka, R., Singh, Z., Hutnick, E., Ruehle, K., … Dahiya, S. (2019). Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. American Journal of Hematology, 94(10), E273–E275.
- Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
  Sim, A. J., Jain, M. D., Figura, N. B., Chavez, J. C., Shah, B. D., Khimani, F., … Robinson, T. J. (2019). Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. International Journal of Radiation Oncology, Biology, Physics, 105(5), 1012–1021.
- Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.
  Bathini, S., Holtzman, N. G., Koka, R., Singh, Z., Wilding, E., Zou, Y., … Dahiya, S. (2019). Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. American Journal of Hematology, 94(8), E216–E219.
- Primary central nervous system posttransplantation lymphoproliferative disorder in an elderly liver transplant recipient.
  Dahiya, S., Ooi, W. B., Ahluwalia, M. S., & Asik, A. (2012). Primary central nervous system posttransplantation lymphoproliferative disorder in an elderly liver transplant recipient. Journal of the American Geriatrics Society, 60(9), 1777–8.
- Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
  Wang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., … Jain, M. D. (2023). Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2201797.
- Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
  Khurana, A., Bailey, M., Iqbal, M., Bansal, R., Lee, C. J., Hunter, B., … Lin, Y. (2022). Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes. BLOOD. AMER SOC HEMATOLOGY.
- Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma
  Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., … Dahiya, S. (2022). Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
  Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentille, C., Mina, A., Arai, S., … Frank, M. J. (2022). The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes. BLOOD. AMER SOC HEMATOLOGY.
- Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
  Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M. S., Good, Z., … Alizadeh, A. A. (2022). Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects. BLOOD. AMER SOC HEMATOLOGY.
- A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Perales, M.-A., Ahmed, S., Dahiya, S., Riedell, P. A., McGuirk, J. P., Oluwole, O. O., … Turtle, C. J. (2022). A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Second-line treatment with CAR T-cell therapy for large B-cell lymphoma.
  Lutfi, F., Patel, A., Mehta, J., Goyal, A., & Dahiya, S. (2023). Second-line treatment with CAR T-cell therapy for large B-cell lymphoma. Clinical Advances in Hematology & Oncology : H&O, 21(4), 170–178.
- Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma.
  Dean, E. A., Kimmel, G. J., Frank, M. J., Bukhari, A., Hossain, N. M., Jain, M. D., … Locke, F. L. (2023). Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma. Blood Advances.
- Second-line Treatment With CAR T-Cell Therapy for Large B-Cell Lymphoma
  Lutfi, F., Patel, A., Mehta, J., Goyal, A., & Dahiya, S. (2023). Second-line Treatment With CAR T-Cell Therapy for Large B-Cell Lymphoma. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 21(4), 170–178.
- Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
  Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A. A., Ghobadi, A., … Locke, F. L. (2023). Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. The New England Journal of Medicine.
- Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).
  Kline, K., Chen, W., Kallen, M. E., Koka, R., Omili, D., Fan, X., … Atanackovic, D. (2023). Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD). Human Vaccines & Immunotherapeutics, 2216116.
- Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy.
  Lutfi, F., Goloubeva, O., Kowatli, A., Gryaznov, A., Kim, D. W., Dureja, R., … Dahiya, S. (2023). Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy. Clinical Lymphoma, Myeloma & Leukemia.
- Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
  Gao, J., Dahiya, S., & Patel, S. A. (2023). Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas. British Journal of Haematology.
- Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.
  Kathari, Y. K., Ahmad, H., Kallen, M. E., Koka, R., Omili, D., Iraguha, T., … Atanackovic, D. (2023). Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells. Haematologica.
- Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma
  Samples, L. S., Sadrzadeh, H., Frigault, M. J., Jacobson, C. A., Hamadani, M., Gurumurthi, A., … Shadman, M. (2023). Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
  Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., … Janakiram, M. (2023). Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer Journal, 13(1), 158.
- TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)
  Nastoupil, L. J., Dahiya, S., Palomba, M. L., Martin Garcia-Sancho, A., Reguera Ortega, J. L., Kuruvilla, J., … Morschhauser, F. (2023). TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Tumor Lysis Syndrome in Leukemias and Lymphomas: A Retrospective Cohort Study of the National Inpatient Sample from 2016 to 2019
  Chitkara, A., Khosla, A., Anamika, F. N. U., Raj, K., & Dahiya, S. (2023). Tumor Lysis Syndrome in Leukemias and Lymphomas: A Retrospective Cohort Study of the National Inpatient Sample from 2016 to 2019. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium.
  Jain, M. D., Jacobs, M. T., Gao, F., Nastoupil, L. J., Spiegel, J. Y., Lin, Y., … Ghobadi, A. (2023). Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium. Blood Advances.
- Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.
  Nie, E. H., Su, Y.-J. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W.-K. K., … Frank, M. J. (2024). Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma. Blood Advances.
- Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
  Kline, K., Luetkens, T., Koka, R., Kallen, M. E., Chen, W., Ahmad, H., … Atanackovic, D. (2024). Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells. Cancer Immunology, Immunotherapy : CII, 73(3), 45.
- A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.
  Atanackovic, D., Iraguha, T., Omili, D., Avila, S. V., Fan, X., Kocoglu, M., … Luetkens, T. (2024). A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products. Cytotherapy.
- Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.
  Lee, D., Goyal, A., Wang, W. L., Ananth, S., Lau, E., Binkley, M. S., … Dahiya, S. (2024). Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient. EJHaem, 5(1), 153–156.
- CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
  Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., … Alizadeh, A. A. (2023). CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. BLOOD. AMER SOC HEMATOLOGY.
- Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
  Bharadwaj, S., Lau, E., Hashmi, A., Hamilton, M. P., Jensen, A., Goyal, A., … Dahiya, S. (2023). Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY.
- Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection
  Ananth, S., Su, Y.-J., Hamilton, M. P., Agarwal, N., Weng, W.-K., Dahiya, S., … Frank, M. J. (2023). Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection. BLOOD. AMER SOC HEMATOLOGY.
- Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium
  Spiegel, J. Y., Jain, M. D., Nastoupil, L. J., Tamaresis, J., Ghobadi, A., Lin, Y., … Dahiya, S. (2023). Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. BLOOD. AMER SOC HEMATOLOGY.
- Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
  Cook, M. R., Shouval, R., Perales, M.-A., Bezerra, E., Niu, A., Dahiya, S., … Locke, F. L. (2023). Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL). BLOOD. AMER SOC HEMATOLOGY.
- TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma
  Morschhauser, F., Dahiya, S., Palomba, M. L., Garcia-Sancho, A. M., Reguera, J. L., Kuruvilla, J., … Nastoupil, L. J. (2023). TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Real World Experience with a Zuma-1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients
  Sainatham, C., Goloubeva, O., Margiotta, P., Alharthy, H., Patel, I., Bukhari, A., … Lutfi, F. (2023). Real World Experience with a Zuma-1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients. BLOOD. AMER SOC HEMATOLOGY.
- Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)
  Cartron, G., Garcia-Sancho, A. M., Reguera, J. L., Dahiya, S., Guo, S., Shi, L., … Izutsu, K. (2023). Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL). BLOOD. AMER SOC HEMATOLOGY.
- Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus
  Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., … McClellan, S. (2023). Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus. BLOOD. AMER SOC HEMATOLOGY.
- Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
  Bharadwaj, S., Lau, E., Goyal, A., Hamilton, M. P., Srinagesh, H., Jensen, A., … Dahiya, S. (2023). Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY.
- Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)
  Goyal, A., Bharadwaj, S., Lee, D., Lau, E., Hamilton, M. P., Jensen, A., … Dahiya, S. (2023). Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY.
- Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)
  Dahiya, S., Spiegel, J. Y., Lee, D., Mohammed, T., Lutfi, F., Goyal, A., … Jain, M. D. (2023). Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY.
- Phase 1 Study of SC291, a Hypoimmune, Allogeneic CD19-Directed CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies (ARDENT) - Initial Clinical Data
  Neelapu, S. S., Budde, L. E., McGuirk, J. P., Dahiya, S., Deol, A., Thompson, P. A., … Schrepfer, S. (2023). Phase 1 Study of SC291, a Hypoimmune, Allogeneic CD19-Directed CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies (ARDENT) - Initial Clinical Data. BLOOD. AMER SOC HEMATOLOGY.
- Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
  Nastoupil, L. J., Bonner, A., Wang, P., Almuallem, L., Desai, J., Fasan, O., … Dahiya, S. (2023). Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL). BLOOD. AMER SOC HEMATOLOGY.
- CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
  Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., … Miklos, D. B. (2024). CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances.
- Management of post-autologous transplant relapse in patients with T-cell lymphomas.
  Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., … Weng, W.-K. K. (2024). Management of post-autologous transplant relapse in patients with T-cell lymphomas. American Journal of Hematology.
- Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series.
  Scala, J. J., Eckrich, M. J., Lipak, K., Yates, B., Yuan, C., Wang, H.-W. W., … Shah, N. N. (2024). Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series. Haematologica.
- Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
  Morschhauser, F., Dahiya, S., Palomba, M. L., Martin Garcia-Sancho, A., Reguera Ortega, J. L., Kuruvilla, J., … Nastoupil, L. J. (2024). Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature Medicine.
- Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
  Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., … Miklos, D. B. (2024). Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. The New England Journal of Medicine, 390(22), 2047–2060.
- Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
  Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., … Dahiya, S. (2024). Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. Journal for Immunotherapy of Cancer, 12(7).
- A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
  Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., … Muffly, L. (2024). A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. Blood.
- CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
  Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., … Miklos, D. B. (2024). CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet (London, England).
- Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
  Morschhauser, F., Dahiya, S., Palomba, M. L., Martin Garcia-Sancho, A., Reguera Ortega, J. L., Kuruvilla, J., … Nastoupil, L. J. (2024). Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature Medicine.
- Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
  Jain, M. D., Spiegel, J. Y., Nastoupil, L. J., Tamaresis, J., Ghobadi, A., Lin, Y., … Dahiya, S. (2024). Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2302786.
- Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH)
  Smith, C. J., Simeone, D. M., Grierson, P., Kirtane, K., Morelli, M. P., Patel, S. P., … Hecht, J. R. (2024). Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment.
  Janelsins, M. C., Van Dyk, K., Hartman, S. J., Koll, T. T., Cramer, C. K., Lesser, G. J., … Dorsey, S. G. (2024). The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment. Journal of the National Cancer Institute.
- Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
  Dahiya, S., Hirayama, A. V., Schuster, S. J., Reguera Ortega, J. L., Morschhauser, F., Garcia-Sancho, A. M., … Lia Palomba, M. (2024). Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review.
  Patel, S. A., Spiegel, J. Y., & Dahiya, S. (2024). Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review. JAMA Oncology.
- TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
  Borchmann, P., Morschhauser, F., Dahiya, S., Palomba, M. L., Garcia-Sancho, A. M., Reguera Ortega, J. L., … Nastoupil, L. J. (2024). TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL). ONCOLOGY RESEARCH AND TREATMENT. KARGER.
- PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS
  Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., … Meyer, E. (2024). PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.
- Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.
  Su, Y.-J. J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., … Frank, M. J. (2025). Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL. Cancer Discovery.
- Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
  Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., … Negrin, R. S. (2025). Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease. Blood.
- Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.
  Samples, L., Sadrzadeh, H., Frigault, M. J., Jacobson, C. A., Hamadani, M., Gurumurthi, A., … Shadman, M. (2025). Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. Blood.
- CCL8/CCL13-producing tumor-associated macrophages linked to poor outcomes after CAR T cell therapy for LBCL
  Mo, K. C., Yeh, C. Y., Hamilton, M. P., Spiegel, J., Desai, M., Ehlinger, Z., … Good, Z. (2024). CCL8/CCL13-producing tumor-associated macrophages linked to poor outcomes after CAR T cell therapy for LBCL. Blood. San Diego.
- Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
  Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A. N. B., … Mikkilineni, L. (2024). Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma. BLOOD. ELSEVIER.
- Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
  Lee, D. (C., Kambhampati, S., Bobillo, M. S. O., Adedokun, B., Shadman, M., Olson, A. L., … Ahmed, S. (2024). Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). BLOOD. ELSEVIER.
- Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
  Wang, J., Bhaskar, S., Adedokun, B., Oluwole, O. O., Metheny, L., Moskop, A., … Locke, F. L. (2024). Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report. BLOOD. ELSEVIER.
- Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies
  Diaz, J. R., Dahiya, S., Sillito, F. E., O'Reilly, M., Rejeski, K., Buecklein, V. L., … Jain, M. D. (2024). Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies. BLOOD. ELSEVIER.
- Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.
  Smith, C. J., Goyal, A., Smith, B. R., Lee, D., Jensen, A., Alexander, J., … Bharadwaj, S. (2025). Lisocabtagene Maraleucel for Richter's Transformation-A Case Series. EJHaem, 6(2), e270011.
- Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma.
  Nastoupil, L. J., Bonner, A., Wang, P., Almuallem, L., Desai, J., Farazi, T., … Dahiya, S. (2025). Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. Experimental Hematology & Oncology, 14(1), 30.
- Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
  Nastoupil, L., Dahiya, S., Palomba, M. L., Garcia-Sancho, A. M., Reguera, J. L., Kuruvilla, J., … Morschhauser, F. (2024). Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up. BLOOD. ELSEVIER.
- Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.
  Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., … Sidana, S. (2025). Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy. Blood Advances.
- Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
  Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A. M., Srinagesh, H., … Alizadeh, A. A. (2024). Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms. BLOOD. ELSEVIER.
- CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
  Kramer, A. M., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., … Frank, M. J. (2024). CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up. BLOOD. ELSEVIER.
- Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
  Muffly, L., Ananth, S., Danley, L., Wagner, C., Kordek, D., Denoble, K., … Smith, M. (2024). Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL. BLOOD. ELSEVIER.
- CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
  Kramer, A. M., Srinagesh, H., Su, Y.-J., Hamilton, M. P., Levine, K., Migliore, E., … Frank, M. J. (2024). CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma. BLOOD. ELSEVIER.
- Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
  Lee, D., Bharadwaj, S., Rana, M. S., Jensen, A., Wang, W., Ghalehsari, N., … Dahiya, S. (2024). Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). BLOOD. ELSEVIER.
- Investigating Treatment Kinetics and Local Response during and after Bridging Radiotherapy Prior to CAR-T Cell Therapy for Lymphomas
  Klebaner, D., Park, N., Marar, M., Frank, M. J., Hiniker, S., Hoppe, R. T., … Binkley, M. S. (2024). Investigating Treatment Kinetics and Local Response during and after Bridging Radiotherapy Prior to CAR-T Cell Therapy for Lymphomas. BLOOD. ELSEVIER.
- Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T)
  Homsy, S., Seki, T., Nguyen, H. D., Shimura, A., Gorantla, N., Phuong, N. J., … Shinozaki, G. (2024). Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T). BLOOD. ELSEVIER.
- NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)
  Ahmed, S., Dipersio, J. F., Md, J. H. E., Diefenbach, C. S., Perales, M. A., Castilla-Llorente, C., … Mcguirk, J. P. (2024). NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL). BLOOD. ELSEVIER.
- Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
  Bobillo, M. S. O., Kambhampati, S., Lee, D., Hunter, B. D., Egini, O., Patel, K., … Frigault, M. (2024). Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. BLOOD. ELSEVIER.
- Cost Consequence and Time Toxicity Model for the Treatment of Third-Line or Later (3L+) Follicular Lymphoma (FL) Using Advanced Therapies: A Comparison of Lisocabtagene Maraleucel (liso-cel) with Mosunetuzumab
  Dahiya, S., Saunders, A. C., Kumar, J., Ngantung, W., & Saeedian, M. (2024). Cost Consequence and Time Toxicity Model for the Treatment of Third-Line or Later (3L+) Follicular Lymphoma (FL) Using Advanced Therapies: A Comparison of Lisocabtagene Maraleucel (liso-cel) with Mosunetuzumab. BLOOD. ELSEVIER.
- Idelalisib (Zydelig®) Maintenance in B-Cell Non-Hodgkin's Lymphoma after High Dose Chemotherapy and Autologous Stem Cell Transplantation
  Yared, J. A., Singh, T., Beitinjaneh, A., Rapoport, A. P., Dahiya, S., Atanackovic, D., … Goloubeva, O. (2024). Idelalisib (Zydelig®) Maintenance in B-Cell Non-Hodgkin's Lymphoma after High Dose Chemotherapy and Autologous Stem Cell Transplantation. BLOOD. ELSEVIER.
- Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma
  Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., … Sidana, S. (2024). Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma. BLOOD. ELSEVIER.
- Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
  Strouse, C., Farooq, U., Shouval, R., Vallurupalli, A., Moskop, A., Jacobson, C. A., … Lin, Y. (2024). Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). BLOOD. ELSEVIER.
- Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma.
  Atanackovic, D., Luetkens, T., Schneider, D., Hu, P., Wang, X., Shetty, A. C., … Kocoglu, M. H. (2025). Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. Nature Communications, 16(1), 6154.
- Noncanonical and mortality-defining toxicities of CAR T cell therapy.
  Rejeski, K., Hill, J. A., Dahiya, S., & Jain, M. D. (2025). Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nature Medicine.
- NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma.
  Ahmed, S., DiPersio, J. F., Essell, J. H., Diefenbach, C., Perales, M.-A. A., Castilla-Llorente, C., … McGuirk, J. P. (2025). NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma. Blood Advances.
- Rapid Peak CAR-T Expansion is Associated with Delayed Neurotoxicity Following Ciltacabtagene Autoleucel in Multiple Myeloma
  Hosoya, H., Velayati, A., Dima, D., Jensen, A., Portuguese, A., Hovanky, V., … Sidana, S. (2025). Rapid Peak CAR-T Expansion is Associated with Delayed Neurotoxicity Following Ciltacabtagene Autoleucel in Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.
  Hamilton, M. P., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B. J., … Alizadeh, A. A. (2025). CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. Research Square.
- Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
  Moscvin, M., Goyal, A., Jensen, A., Epstein, D., Hovanky, V., Mikkilineni, L., … Sidana, S. (2025). Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma
  Goyal, A., Bharadwaj, S., Lau, E., Jensen, A., Hamilton, M., Lee, C., … Dahiya, S. (2025). Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Baseline Metabolic Tumor Volume (MTV) as a Prognostic Marker in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory Large B-Cell Lymphoma
  Rana, M., Ghalehsari, N., Jensen, A., Lee, D., Wang, W., & Dahiya, S. (2025). Baseline Metabolic Tumor Volume (MTV) as a Prognostic Marker in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory Large B-Cell Lymphoma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
  Srinagesh, H. K., Kramer, A. M., Baird, J. H., Reschke, A., Sahaf, B., Cancilla, J., … Frank, M. J. (2025). Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Blood Cancer Discovery.
- Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.
  Lee, D., & Dahiya, S. (2025). Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma. Haematologica.
- Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.
  Klebaner, D., Park, N. J., Marar, M., Frank, M., Hiniker, S. M., Hoppe, R. T., … Binkley, M. S. (2025). Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas. Leukemia & Lymphoma, 1–8.
- Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL
  Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., … Smith, M. (2025). Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL. BLOOD. ELSEVIER.
- CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma
  Kramer, A. M., Murty, T., Chen, Y., Rodrigues, K., Hamilton, M., Desai, M., … Frank, M. (2025). CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma. BLOOD. ELSEVIER.
- ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C
  Van Dorp, S., Stussi, G., Frustaci, A. M., Flinn, S. C. I., Crees, Z., Baird, J., … Tiacci, E. (2025). ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C. BLOOD. ELSEVIER.
- Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT
  Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., … Kennedy, V. (2025). Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT. BLOOD. ELSEVIER.
- Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study
  Lee, D. (C., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., … Dahiya, S. (2025). Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study. BLOOD. ELSEVIER.
- Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post-CAR-T therapy
  Rana, M., Ghalehsari, N., Jensen, A., Lee, D. (C., Park, N., Goyal, A., … Dahiya, S. (2025). Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post-CAR-T therapy. BLOOD. ELSEVIER.
- Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy
  Ananth, S., Mallampet, J., Chang, B., Agarwal, N., Kong, K., Sahaf, B., … Frank, M. (2025). Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy. BLOOD. ELSEVIER.
- Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
  Sidana, S., Reid, B., Dima, D., Peres, L., Gaballa, M., Banerjee, R., … Hansen, D. (2025). Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality. BLOOD. ELSEVIER.
- Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma
  Hosoya, H., Velayati, A., Dima, D., Jensen, A., Portuguese, A., Hovanky, V., … Sidana, S. (2025). Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma. BLOOD. ELSEVIER.
- Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results
  Westin, J., Chavez, J., Schuster, S. J., Vucinic, V., Young, P. A., Johnson, P. C., … Barba, P. (2025). Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results. BLOOD. ELSEVIER.
- Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study
  Karmali, R., Morschhauser, F., Izutsu, K., Palomba, L., Ardeshna, K., Hill, B., … Abramson, J. (2025). Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study. BLOOD. ELSEVIER.
- CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity
  Srinagesh, H., Kramer, A. M., Hamilton, M., Su, Y.-J., Kozy, K., Jackson, L., … Frank, M. (2025). CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity. BLOOD. ELSEVIER.
- Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation
  Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., … Kennedy, V. (2025). Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation. BLOOD. ELSEVIER.
- Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study
  Villar-Prados, A., Kim, P., Sutherland, K., Negrin, R., Arai, S., Frank, M., … Meyer, E. (2025). Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study. BLOOD. ELSEVIER.
- Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)
  Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., … Sidana, S. (2025). Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM). BLOOD. ELSEVIER.
- From response to rupture: Evaluating GI perforation after CD19 CAR-T in LBCL
  Velayati, A., Rana, M., Jensen, A., Lee, D. (C., Ghalehsari, N., Goyal, A., … Dahiya, S. (2025). From response to rupture: Evaluating GI perforation after CD19 CAR-T in LBCL. BLOOD. ELSEVIER.
- Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium
  Reshef, R., Jensen, A., Gordillo, C., Reid, B., Dima, D., Peres, L., … Sidana, S. (2025). Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium. BLOOD. ELSEVIER.
- A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363
  Dahiya, S., Ulrickson, M., Yared, J., Reagan, P., Voorhees, T., Reshef, R., … Ahmed, S. (2025). A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363. BLOOD. ELSEVIER.
- Pre-treatment CDI9 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL
  Spiegel, J., Oak, J., Rana, M., Jensen, A., Lee, D. (C., Nguyen-Mau, S.-M., … Dahiya, S. (2025). Pre-treatment CDI9 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL. BLOOD. ELSEVIER.
- Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged > 75) with relapsed or refractory multiple myeloma (RRMM)
  Velayati, A., Jensen, A., Dima, D., Rana, M., Peres, L., Shune, L., … Sidana, S. (2025). Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged > 75) with relapsed or refractory multiple myeloma (RRMM). BLOOD. ELSEVIER.
- Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
  Crombie, J. L., Ahmed, S., Frigault, M. J., Hunter, B. D., Palomba, M. L., Mirza, A.-S. S., … Isufi, I. (2026). Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma. Blood.
- AI-Quantified Patient Frailty Predicts Clinical Response to CAR-T
  Smith, C. J., Fettahoglu, A., Johnston, A., Smith, B. R., Mikkilinenni, L., Sidana, S., … Bharadwaj, S. (2026). AI-Quantified Patient Frailty Predicts Clinical Response to CAR-T. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC.
- Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy
  Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., … On, S. (2026). Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC.
- Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients
  Rana, M. S., Kaveh, N., Jensen, A., Kennedy, V. E., Weng, W.-K., Smith, M., … Sidana, S. (2026). Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC.
- Developing Comprehensive Strategies for Managing Behaviorally Dysregulated Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Patients Undergoing Chimeric Antigen Receptor (CAR) T cell Therapy
  Latchford, T. M., Davis, B., Scott, B. J., Dahiya, S., Fishman, D., & Lahijani, S. (2026). Developing Comprehensive Strategies for Managing Behaviorally Dysregulated Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Patients Undergoing Chimeric Antigen Receptor (CAR) T cell Therapy. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC.
- Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL).
  Furqan, F., Hemmer, M. T., Tees, M. T., Baird, J. H., Holter-Chakrabarty, J. L., Mcclune, B. L., … Lin, Y. (2025). Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
  Dahiya, S., Ulrickson, M., Topp, M. S., Kersten, M. J., Yared, J., Reagan, P. M., … Nastoupil, L. J. (2025). A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.
  Wang, W. L., Lee, D., Cheung, E., Jensen, A., Rana, M. S., Goyal, A., … Dahiya, S. (2026). Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS. Blood Advances.
- Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.
  Mirza, A.-S. S., Hosing, C., Foss, F., Kim, S., Moskop, A., Oloyede, T., … Gowda, L. (2026). Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas. Blood Neoplasia, 3(2), 100187.
- Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucel and Brexucabtagene Autoleucel for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis
  Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., … Muffly, L. S. (2026). Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucel and Brexucabtagene Autoleucel for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC.
- Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.
  Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., … Kennedy, V. (2026). Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy.
- Enhancing the Safety of Ciltacabtagene Autoleucel in Relapsed Multiple Myeloma (MM):Identification of Potentially Modifiable Risk-Factors Associated with Delayed Neurotoxicity and Non-Relapse Mortality
  Sidana, S., Reid, B., Dima, D., Peres, L. C., Gaballa, M., Banerjee, R., … Hansen, D. K. (2026). Enhancing the Safety of Ciltacabtagene Autoleucel in Relapsed Multiple Myeloma (MM):Identification of Potentially Modifiable Risk-Factors Associated with Delayed Neurotoxicity and Non-Relapse Mortality. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC.
- Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma
  Westin, J., Chavez, J. C., Schuster, S. J., Vucinic, V., Young, P. A., Johnson, P. C., … Barba, P. (2026). Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC.
- A Phase 1 Study of KITE-753 or KITE-363 in Patients with Relapsed/Refractory B-cell Lymphoma: Initial Safety and Preliminary Efficacy of KITE-753 and Updated Results of KITE-363
  Dahiya, S., Ulrickson, M. L., Yared, J. A., Reagan, P. M., Voorhees, T., Reshef, R., … Ahmed, S. (2026). A Phase 1 Study of KITE-753 or KITE-363 in Patients with Relapsed/Refractory B-cell Lymphoma: Initial Safety and Preliminary Efficacy of KITE-753 and Updated Results of KITE-363. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC.
- Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.
  Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., … Sidana, S. (2026). Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy. Blood Cancer Journal.
- Brexu-cel plus dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia
  Jeyakumar, N., Shiraz, P., Weber, E., Kanegai, A., Wagner, C., Ramakrishnan, A., … Muffly, L. (2026). Brexu-cel plus dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.
  Ananth, S., Agarwal, N., Sahaf, B., Jacob, A., Lee, L. W., Simmons, H., … Frank, M. J. (2026). Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse. American Journal of Hematology.
- Measurable residual disease (MRD) by circulating tumor (ct) DNA in patients (pt) with R/R follicular lymphoma (FL) treated with lisocabtagene maraleucel (liso-cel) in TRANSCEND FL.
  Avilion, A., Ansari, S., Okal, A., Thompson, E. G., Strocchia, M., Bar, M., … Peiser, L. (2026). Measurable residual disease (MRD) by circulating tumor (ct) DNA in patients (pt) with R/R follicular lymphoma (FL) treated with lisocabtagene maraleucel (liso-cel) in TRANSCEND FL. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
  Dahiya, S., Voorhees, T., Ulrickson, M., Yared, J., Reagan, P. M., Kersten, M. J., … Ahmed, S. (2026). KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.
  Hosoya, H., Velayati, A., Dima, D., Jensen, A., Portuguese, A. J., Hovanky, V., … Sidana, S. (2026). Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma. Blood.
- Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.
  Ahmed, S., Martin Garcia-Sancho, A., Reguera-Ortega, J. L., Cartron, G., Rapoport, A. P., Izutsu, K., … Morschhauser, F. (2026). Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL. Blood.
- Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas.
  Pandey, T., Samat, D., Dahiya, S., & Patel, S. A. (2026). Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas. Frontiers in Immunology, 17, 1900443.
- Up and coming early phase CAR T-cell Therapy for treating relapsed or refractory large B-cell lymphoma.
  Lee, D., Rana, M., Esmali, A., & Dahiya, S. (2026). Up and coming early phase CAR T-cell Therapy for treating relapsed or refractory large B-cell lymphoma. Expert Opinion on Investigational Drugs.
- ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy.
  Perales, M.-A. A., Dietrich, J., Gust, J., Santomasso, B., Rejeski, K., Hansen, D., … Locke, F. L. (2026). ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy. Transplantation and Cellular Therapy.
- Measurable Residual Disease by Circulating Tumor DNA in Patients With Third-Line or Later Relapsed or Refractory Follicular Lymphoma Treated With Lisocabtagene Maraleucel in TRANSCEND FL
  Avilion, A., Ansari, S., Okal, A., Thompson, E. G., Strocchia, M., Bar, M., … Peiser, L. (2026). Measurable Residual Disease by Circulating Tumor DNA in Patients With Third-Line or Later Relapsed or Refractory Follicular Lymphoma Treated With Lisocabtagene Maraleucel in TRANSCEND FL. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. ELSEVIER SCIENCE INC.
- A Multicenter Phase 1 Study of KITE-753 in Patients With Relapsed/Refractory B-Cell Lymphoma: Updated Safety and Efficacy Results
  Dahiya, S., Ulrickson, M., Yared, J., Reagan, P., Voorhees, T., Goy, A., … Ahmed, S. (2026). A Multicenter Phase 1 Study of KITE-753 in Patients With Relapsed/Refractory B-Cell Lymphoma: Updated Safety and Efficacy Results. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. ELSEVIER SCIENCE INC.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Practice Locations

Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive Palo Alto, CA

Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive

875 Blake Wilbur Dr, Clinic E Fl 1

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(36 Ratings)

Overall Rating

4.8/5

View Ratings by Category

5.0/5

Friendliness

4.9/5

Explanations

4.9/5

Listens

4.9/5

Care provider's efforts to include you in decisions about your care

4.8/5

Recommended to others

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Review Summary

Dr. Dahiya is regarded as an excellent and knowledgeable physician. Many find him to be compassionate, caring, and friendly, with a focus on the patient's best interest. His expertise is frequently noted.

The summary was created by AI, based on recent patient reviews. Learn more

Was this result useful to you?

Patient Reviews

(23 reviews)

My family and I will be forever grateful to Dr Dahiya and the entire CAR-T team at Stanford. From the very beginning of my journey, Dr Dahiya provided exceptional medical care with remarkable compassion, kindness, patience and genuine concern. This was an extensive journey of nearly 2 months, and there were moments when I faced difficult complications. Through every challenge, he remained calm, reassuring, incredibly attentive, always taking time to explain everything thoroughly and answer every question with patience and empathy. He transformed what could have been an overwhelming experience into one filled with hope, confidence and trust. The nurses and every member of the CAR-T team were equally outstanding. Their professionalism, warmth, compassion and dedication were evident every single day. Today, my family and I are incredibly thankful that I successfully completed the CAR-T treatment and I’m cancer-free! We know that this outcome reflects the exceptional skill, dedication, and teamwork of everyone involved in my care. Traveling hundreds of miles from San Diego to Stanford was unquestionably the right decision. We couldn’t have asked for a better and more compassionate team. Dr Dahiya has our deepest admiration and gratitude, and we will never forget the extraordinary care he gave me and the kindness he showed my entire family.

Aug 2026

•

Verified SHC Patient

Dr. Dahiya is the reason I came to Stanford for treatment, I had other choices but he was the key to my decision. He is brilliant, compassionate, warm and gives me hope. His treatment has offered me the opportunity for longer life. I am forever grateful to him. I trust him completely to take care of me.

Jul 2026

•

Verified SHC Patient

Thank you Dr. Dahiya for all that you do.

May 2026

•

Verified SHC Patient

I am coming to Stanford for my stem cell treatment because of Dr. Dahiya and I believe he provides me the best possible chance at durable remission for my blood cancer. He is attentive, caring, proactive, warm, and kind. He makes me feel comfortable and respected. He listens patiently and answers all my questions. I chose Stanford over UCLA for my treatment because of how he treated me. And how I believe he cares about healing me. I love having him as my doctor and I trust him.

May 2026

•

Verified SHC Patient

He’s a Great Doctor and shows a personal concern regarding my age and physical health.

May 2026

•

Verified SHC Patient

Dr. Dahiya answered every question we had thoroughly.

Apr 2026

•

Verified SHC Patient

Good doctor, caring, smart, demonstrates knowledgability and practicality in administrating his BMT group.

Mar 2026

•

Verified SHC Patient

Dr. Saurabh Dahiya is a top doctor in my mind. I feel comfortable with him and trust his decisions on my behalf.

Mar 2026

•

Verified SHC Patient

Sending gratitude for his intelligence and knowledge regarding oncology.

Feb 2026

•

Verified SHC Patient

He's very smart and accomplished and I only wish that the therapy he had me follow was not successful. I believe him to be caring and empathetic, and striving dilligently on behalf of his patients.

Jan 2026

•

Verified SHC Patient

He and his staff are very kind and respectful

Nov 2025

•

Verified SHC Patient

He helped me feel more comfortable and optimistic with my treatment prognosis.

Nov 2025

•

Verified SHC Patient

Compassionate and smart. Great source of knowledge about CAR-T.

Jul 2025

•

Verified SHC Patient

Dr. Dahiya is excellent - knowledgeable, and caring.

Feb 2025

•

Verified SHC Patient

Thank you for your excellent care. I really appreciate your expertise and compassion

Nov 2024

•

Verified SHC Patient

Staff is excellent and helpful

Nov 2024

•

Verified SHC Patient

very nice easy to get along with he definitely has my best interest

Nov 2024

•

Verified SHC Patient

Very detailed and he is a very good Dr

Aug 2024

•

Verified SHC Patient

Very nice Doctor. Personable and very good at taking care of me.

Jul 2024

•

Verified SHC Patient

I think he is very dedicated to his work as an Oncologist and with CART Cell Therapy and feel very privileged to have him as my Oncologist.

May 2024

•

Verified SHC Patient

Greatest doc in world!!!

May 2024

•

Verified SHC Patient

He is a excellent doctor.

Mar 2024

•

Verified SHC Patient

Excellent, professional, kind, understanding.

Dec 2023

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Saurabh Dahiya, MD, FACP

Hematologist-Oncologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Publications

Clinical Trials

Practice Locations

Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Review Summary

Patient Reviews

(23 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Saurabh Dahiya, MD, FACP

Hematologist-Oncologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Publications

Clinical Trials

Practice Locations

Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Review Summary

Patient Reviews

(23 reviews)

Referring Physicians

PHYSICIAN HELPLINE